Traditional cardiovascular (CV) risk prediction models may not apply accurately to patients with HIV who may develop the cardiovascular disease younger than usual, said Jorge Plutzky, MD, director of the Vascular Disease Prevention Program and director of Preventive Cardiology at Brigham and Women’s Hospital and associate professor of medicine at Harvard Medical School.
Traditional cardiovascular risk prediction models may not apply accurately to patients with HIV who may develop the cardiovascular disease younger than usual, said Jorge Plutzky, MD, director of the Vascular Disease Prevention Program and director of Preventive Cardiology at Brigham and Women’s Hospital and associate professor of medicine at Harvard Medical School.
Transcript
Why is there a need for different cardiovascular disease prediction models for people living with HIV? How do current prediction models fall short?
The occurrence of cardiovascular disease in patients with HIV has raised questions about prediction models that we typically use may not be relevant. These patients could be younger, they have other issues going on, they’re on other medicines. There may be this issue with inflammation as a driver of it. And so, it has prompted the question of stepping back and looking to what extent do our traditional risk prediction models apply in patients with HIV, because they just may be different.
They may also require consideration of the same kinds of drivers of disease but being present in people who are younger. And so rather than making an assumption that this couldn't be a problem, now, because someone is too young, embracing the fact that one so has to consider whether or not that's an issue, given what we see epidemiologically.
It's also interesting that that's those same sorts of issues apply in other diseases. So, we're involved with some very exciting, important work looking at cardiovascular risk in rheumatologic diseases. And I have colleagues at the Brigham who are really focused on that. And it goes hand in hand with the idea that maybe inflammation is a contributor, and also the fact that we now have much more potent anti-inflammatory drugs that are being used in rheumatology, that may uncouple the usual patterns that we see with changes in lipids in terms of cardiovascular disease, as their inflammation gets controlled. Lipid and cholesterol parameters are influenced by inflammation and acute phase responses that can occur with inflammatory diseases, the therapies can shift that.
And so, the numbers have been demonstrated as having patterns that are surprising, and maybe not what are predicted in terms of outcomes and is forcing this question of revisiting, how we predict cardiovascular risk in those kinds of settings like HIV and rheumatologic disorders?
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More
Patients With Advanced, Recurrent Melanoma May Experience Lasting AEs From ICM Therapy
May 9th 2024A cross-sectional, mixed-methods study found that adverse effects (AEs) can occur even after 1 year of treatment with immune checkpoint modulator (ICM) therapy in patients with melanoma.
Read More